Metastatic ovarian and primary peritoneal cancer: Assessing chemotherapy response with diffusion-weighted MR imaging - Value of histogram analysis of apparent diffusion coefficients

Radiology

Volumn 261, Issue 1, 2011, Pages 182-192

  Kyriazi, Stavroula ^a   Collins, David J ^a   Messiou, Christina ^a   Pennert, Kjell ^a   Davidson, Robert L ^a   Giles, Sharon L ^a   Kaye, Stan B ^a   DeSouza, Nandita M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; DOXORUBICIN; IDRONOXIL; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ACCURACY; ADULT; AGED; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; FEMALE; HISTOGRAM; HUMAN; MULTIPLE CYCLE TREATMENT; OBSERVER VARIATION; OVARY METASTASIS; PERITONEUM CANCER; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RECURRENT CANCER; REPRODUCIBILITY;

ADULT; AGED; AGED, 80 AND OVER; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80053068641     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11110577     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300.
2. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21(17):3194-3200. (Pubitemid 46606249)
3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51(1):15-36. (Pubitemid 32166444)
4. Oaknin A, Barretina P, Pérez X, et al. CA-125 response patterns in patients with recurrent ovarian cancer treated with pegylated liposomal doxorubicin (PLD). Int J Gynecol Cancer 2010;20(1):87-91.
5. Ferrandina G, Ludovisi M, Corrado G, Carone V, Petrillo M, Scambia G. Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2008;109(2):187-193.
6. Chen CY, Li CW, Kuo YT, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants - initial experience. Radiology 2006;239(2):448-456.
7. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008;248(3):894-900.
8. Harry VN, Semple SI, Gilbert FJ, Parkin DE. Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer. Gynecol Oncol 2008;111(2):213-220.
9. Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010;31(1):60-66.
10. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252(1):182-189.
11. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings - a feasibility study. AJR Am J Roentgenol 2009;193(2):461-470.
12. Sala E, Priest AN, Kataoka M, et al. Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla - technical development. Eur Radiol 2010;20(2):491-496.
13. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9(3):167-181.
14. Baek SJ, Park JY, Kim DY, et al. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol 2008;19(4):223-228.
15. Braithwaite AC, Dale BM, Boll DT, Merkle EM. Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 2009;250(2):459-465.
16. Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011;21(2):419-423.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
18. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8(2):135-160. (Pubitemid 29425900)
19. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86(2):420-428.
20. Johnson RA, Wichern DW. Applied multivariate statistical analysis. 5th ed. Englewood Cliffs, NJ: Prentice Hall, 2002.
21. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echoplanar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9(1):53-60. (Pubitemid 29068231)
22. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224(1):177-183. (Pubitemid 34680392)
23. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241(3):839-846. (Pubitemid 46190551)
24. Tozer DJ, Jäger HR, Danchaivijitr N, et al. Apparent diffusion coefficient histograms may predict low-grade glioma subtype. NMR Biomed 2007;20(1):49-57.
25. Nowosielski M, Recheis W, Goebel G, et al. ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology 2011;53(4):291-302.
26. Park SH, Moon WK, Cho N, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010;257(1):56-63.
27. Sun YS, Zhang XP, Tang L, et al. Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 2010;254(1):170-178.
28. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007;188(4):1001-1008. (Pubitemid 46496932)
29. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360(9329):307-308. (Pubitemid 34874724)
30. King AD, Mo FK, Yu KH, et al. Squamous cell carcinoma of the head and neck: diffusion-weighted MR imaging for prediction and monitoring of treatment response. Eur Radiol 2010;20(9):2213-2220.
31. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coeffi cient, and relative cerebral blood volume. J Magn Reson Imaging 2004;19(5):546-554. (Pubitemid 38619916)